{"id":34608,"date":"2025-06-03T17:25:35","date_gmt":"2025-06-03T09:25:35","guid":{"rendered":"https:\/\/flcube.com\/?p=34608"},"modified":"2025-06-03T17:25:36","modified_gmt":"2025-06-03T09:25:36","slug":"longbio-pharma-secures-rmb-200-million-series-c-funding-for-clinical-studies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34608","title":{"rendered":"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies"},"content":{"rendered":"\n

China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The funding was co-led by Highlight Capital and existing investor Qiming Venture Partners, with additional contributions from Blue Bay Fund, TruMed Investment, Sanyi Capital, and other investors. The proceeds will be used to support the Phase III clinical study and commercialization of its lead asset LP-003, as well as the clinical development of investigational drug LP-005 across multiple indications.<\/p>\n\n\n\n

LP-003 and LP-005 Development<\/strong>
LP-003, a next-generation anti-IgE antibody, is currently in Phase III study for allergic rhinitis, with marketing filing expected in early 2026. Meanwhile, LP-005, a first-in-class complement bifunctional antibody, is undergoing Phase II study for paroxysmal nocturnal hemoglobinuria (PNH). Clinical studies for LP-005 in complement-mediated nephropathy, including IgA nephropathy and C3 glomerulopathy, are scheduled to commence within this year.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million…<\/p>\n","protected":false},"author":1,"featured_media":34609,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,2483],"class_list":["post-34608","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-longbio-pharma"],"yoast_head":"\nLongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The funding was co-led by Highlight Capital and existing investor Qiming Venture Partners, with additional contributions from Blue Bay Fund, TruMed Investment, Sanyi Capital, and other investors. The proceeds will be used to support the Phase III clinical study and commercialization of its lead asset LP-003, as well as the clinical development of investigational drug LP-005 across multiple indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34608\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies\" \/>\n<meta property=\"og:description\" content=\"China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The funding was co-led by Highlight Capital and existing investor Qiming Venture Partners, with additional contributions from Blue Bay Fund, TruMed Investment, Sanyi Capital, and other investors. The proceeds will be used to support the Phase III clinical study and commercialization of its lead asset LP-003, as well as the clinical development of investigational drug LP-005 across multiple indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34608\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-03T09:25:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-03T09:25:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0310.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies\",\"datePublished\":\"2025-06-03T09:25:35+00:00\",\"dateModified\":\"2025-06-03T09:25:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608\"},\"wordCount\":157,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0310.webp\",\"keywords\":[\"Biotech\",\"Finance\",\"Longbio Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34608#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34608\",\"name\":\"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0310.webp\",\"datePublished\":\"2025-06-03T09:25:35+00:00\",\"dateModified\":\"2025-06-03T09:25:36+00:00\",\"description\":\"China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The funding was co-led by Highlight Capital and existing investor Qiming Venture Partners, with additional contributions from Blue Bay Fund, TruMed Investment, Sanyi Capital, and other investors. The proceeds will be used to support the Phase III clinical study and commercialization of its lead asset LP-003, as well as the clinical development of investigational drug LP-005 across multiple indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34608\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0310.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0310.webp\",\"width\":1080,\"height\":608,\"caption\":\"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34608#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies - Insight, China's Pharmaceutical Industry","description":"China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The funding was co-led by Highlight Capital and existing investor Qiming Venture Partners, with additional contributions from Blue Bay Fund, TruMed Investment, Sanyi Capital, and other investors. The proceeds will be used to support the Phase III clinical study and commercialization of its lead asset LP-003, as well as the clinical development of investigational drug LP-005 across multiple indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34608","og_locale":"en_US","og_type":"article","og_title":"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies","og_description":"China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The funding was co-led by Highlight Capital and existing investor Qiming Venture Partners, with additional contributions from Blue Bay Fund, TruMed Investment, Sanyi Capital, and other investors. The proceeds will be used to support the Phase III clinical study and commercialization of its lead asset LP-003, as well as the clinical development of investigational drug LP-005 across multiple indications.","og_url":"https:\/\/flcube.com\/?p=34608","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-03T09:25:35+00:00","article_modified_time":"2025-06-03T09:25:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0310.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34608#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34608"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies","datePublished":"2025-06-03T09:25:35+00:00","dateModified":"2025-06-03T09:25:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34608"},"wordCount":157,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34608#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0310.webp","keywords":["Biotech","Finance","Longbio Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34608#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34608","url":"https:\/\/flcube.com\/?p=34608","name":"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34608#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34608#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0310.webp","datePublished":"2025-06-03T09:25:35+00:00","dateModified":"2025-06-03T09:25:36+00:00","description":"China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The funding was co-led by Highlight Capital and existing investor Qiming Venture Partners, with additional contributions from Blue Bay Fund, TruMed Investment, Sanyi Capital, and other investors. The proceeds will be used to support the Phase III clinical study and commercialization of its lead asset LP-003, as well as the clinical development of investigational drug LP-005 across multiple indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34608#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34608"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34608#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0310.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0310.webp","width":1080,"height":608,"caption":"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34608#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0310.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34608"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34608\/revisions"}],"predecessor-version":[{"id":34610,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34608\/revisions\/34610"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34609"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}